Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2008 1
2017 1
2020 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.
Jahnmatz M, Richert L, Al-Tawil N, Storsaeter J, Colin C, Bauduin C, Thalen M, Solovay K, Rubin K, Mielcarek N, Thorstensson R, Locht C; BPZE1 study team. Jahnmatz M, et al. Among authors: thalen m. Lancet Infect Dis. 2020 Nov;20(11):1290-1301. doi: 10.1016/S1473-3099(20)30274-7. Epub 2020 Jul 17. Lancet Infect Dis. 2020. PMID: 32687804 Clinical Trial.
Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.
Lin A, Apostolovic D, Jahnmatz M, Liang F, Ols S, Tecleab T, Wu C, van Hage M, Solovay K, Rubin K, Locht C, Thorstensson R, Thalen M, Loré K. Lin A, et al. Among authors: thalen m. J Clin Invest. 2020 May 1;130(5):2332-2346. doi: 10.1172/JCI135020. J Clin Invest. 2020. PMID: 31945015 Free PMC article. Clinical Trial.